GlobeNewsWire
02 Oct 2026, 23:34 UTC · 2h ago
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
Impact · against what's priced in
The news is largely neutral for UNCY as the core allegations regarding manufacturing failures and FDA delays are already known to the market. The only novel element is the specific legal deadline for lead plaintiff appointment, which is a procedural detail with limited immediate impact on valuation.
- UNCY−0.10
No priced-in read yet





